Clinical Trial Search

Primary: Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.92; 0.95 AECOPD events/person-year — p=0.941

Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants

Primary: Change From Baseline in Inspiratory Capacity (IC) at Isotime — 0.0035; 0.07 liter — p=0.0087

Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants

Primary: Device Tidal Volume — 180 mL

Primary: Exertional Dyspnea Intensity at Isotime Exercise. — 3.9; 3.4 units on a scale — p=0.090

Primary: Percentage of Participants Whose Post-albuterol Forced Expiratory Volume in One Second (FEV1) Was <80% Predicted Normal — 70; 30 percentage of participants

Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52

Primary: Number of Subjects With Four Week Continuous Quit Rate (CQR) — 105; 22 participants — p=<0.0001

Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85

Primary: Mean Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.78; 0.71 AECOPD events/year — p=0.645

Primary: Change From Baseline in Trough FEV1 at Treatment Visit Day 7 Compared to Placebo. — -0.0282; -0.0156; 0.0540; 0.0806 liters — p=0.9730

Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants

Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 3 Hours (AUC0-3h) After 4 Weeks of Treatment. — 0.250; -0.086…

Primary: Time Spent in Physical Activity as Measured by Upright Time (Minutes Per Day) Monitored by ActivPal Monitor — 278; 269; 293; 285 minutes per day

Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day

Primary: FEV1, E0-4; the Average Value at Visit 5 From Before to 4 Hours After Morning Dose (Peak Effect) — 0.21; 0.17; 0.14; 0.16 Litre

Primary: Patients Who Experienced at Least One Adverse Events(s) — 9; 10; 6 Participants

Primary: Number of Patients Who Were Cured — 91; 117 Participants — p=<0.05

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks — 1.408; 1.301 Liters

Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001

Primary: Pre-dose FEV1 — 1.079; 1.009 Ratio — p=<.0001

Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 0.99; 1.21; 1.09; 1.17 Exacerbations per year — p=0.0638

Primary: Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) — 0.0009; 0.1055; 0.1333; 0.1336 liters — p=0.0043

Primary: Incidence of Adverse Events — 3; 3; 6; 7 Participants

Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 1.19; 1.03; 1.24 Exacerbations per year — p=0.6490

Primary: Percentage of Participants With COPD Who Rate the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrate Correct Use of the Inhaler at the End of…

Primary: Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4 — 0.203; 0.209; 0.257; 0.196 Liters — p=<0.001

Primary: Clinical Exacerbation of COPD (CE-COPD) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CE-COPD — 28 percentage of participants

Primary: Absolute Monocyte Count in BAL Post-LPS Challenge — 398; 514.4 x10^4 cells/mL